Earnings Novo Nordisk’s September Reckoning: A Raised Forecast That Failed to Soothe
The arithmetic at Novo Nordisk is getting harder to follow. On one page of the ledger, the Danish drugmaker delivered a second-quarter performance that beat its own expectations, lifted its...